KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer

KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer

Purpose The KRAS gene frequently mutates in colorectal cancer (CRC). Here we investigated the prognostic and predictive role of KRAS mutation in patients with stage II or III CRC. Experimental design A consecutive cohort of patients with stage II or III CRC from a single center database was studied....

Full description

Saved in:
Bibliographic Details
Main Authors: Yanhong Deng, Li Wang, Shuyun Tan, George P. Kim, Ruoxu Dou, Dianke Chen, Yue Cai, Xinhui Fu, Lei Wang, Jun Zhu, Jianping Wang
Format: Article
Language:English
Published: Wiley 2015-08-01
Series:Molecular Oncology
Subjects:
KRAS
Adjuvant chemotherapy
Colorectal cancer
FOLFOX
Online Access:https://doi.org/10.1016/j.molonc.2015.03.006
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1016/j.molonc.2015.03.006

Similar Items